Physician profile
David B Engler
NPI 1669477568
$13,109.46
in general payments reported to CMS, 2019-2025
35 companies · $2,211 in 2025
The $2,211 reported for 2025 was more than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,497 · 2020: $1,117 · 2021: $1,946 · 2022: $1,959 · 2023: $1,997 · 2024: $2,382 · 2025: $2,211.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,590.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,589.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,644.16 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Takeda Pharmaceuticals U.S.A., INC. | $1,344.69 | 2020-2025 | Cuvitru, Takhzyro |
| Glaxosmithkline, LLC. | $1,236.86 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Csl Behring | $1,205.71 | 2019-2025 | Haegarda, Hizentra, Andembry |
| Biocryst US Sales Co., LLC | $988.12 | 2021-2025 | Orladeyo |
| Grifols USA, LLC | $666.76 | 2019-2025 | Xembify |
| Pfizer INC. | $643.63 | 2019-2025 | |
| Genzyme Corporation | $629.06 | 2019-2025 | |
| Genentech USA, INC. | $601.65 | 2019-2025 | Xolair |
| Novartis Pharmaceuticals Corporation | $579.81 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $460.83 | 2019-2025 | Dupixent |
| Blueprint Medicines Corporation | $368.80 | 2023-2025 | Ayvakit, Gavreto |
| Amgen INC. | $360.82 | 2021-2025 | Tezspire |
| Kaleo, INC. | $340.85 | 2019-2024 | Auvi-Q |
| Shire North American Group INC | $241.76 | 2019 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharming Healthcare, INC. | $233.46 | 2020-2025 | Ruconest |
| Ionis Pharmaceuticals, INC. | $215.45 | 2025 | Dawnzera |
| Alk-Abello, INC | $203.01 | 2019-2023 | Odactra, Ragwitek, Grastek |
| Leo Pharma INC. | $174.35 | 2022-2023 | Adbry |
| Boehringer Ingelheim Pharmaceuticals, INC. | $151.52 | 2019-2021 | |
| Mylan Specialty L.P. | $127.72 | 2019-2024 | Yupelri |
| Genentech, INC. | $117.09 | 2025 | Xolair |
| Hospira, INC. | $110.74 | 2024-2025 | |
| Octapharma USA, INC. | $97.39 | 2020-2024 | Cutaquig |
| Teva Pharmaceuticals USA, INC. | $55.33 | 2021 | |
| Sunovion Pharmaceuticals INC. | $50.92 | 2019 | |
| Optinose US, INC. | $48.34 | 2021-2025 | |
| Biocryst Pharmaceuticals, INC. | $40.96 | 2020 | |
| Galderma Laboratories, L.P. | $34.58 | 2025 | Nemluvio |
| Gc Biopharma USA, INC. | $33.50 | 2025 | Alyglo |
| Ars Pharmaceuticals Operations, INC. | $23.73 | 2025 | Neffy |
| Incyte Corporation | $22.40 | 2021 | |
| Aimmune Therapeutics, INC. | $20.04 | 2021 | |
| Adma Biomanufacturing LLC | $18.53 | 2020 | |
| Jubilant Hollisterstier LLC | $16.89 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Engler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.